NEW YORK ( TheStreet) -- CHANGE IN RATINGS Cigna ( CI) upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $56 price target. New analyst also placed the company on the US Focus List. Company can continue to grow the business and return capital to shareholders. $56 price target. Cepheid ( CPHD) rated new Hold at Cantor. Valuation call, based on a $40 price target. Equifax ( EFX) rated new Hold at Deutsche Bank. Valuation call, based on a $47 price target. Humana ( HUM) downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. $74 price target. New analyst has a $74 price target. Louisiana-Pacific ( LPX) upgraded at BofA/Merrill from Underperform to Buy, Bank of America/Merrill Lynch said. Valuation call, based on a $16 price target. Louisiana-Pacific downgraded at Deutsche. LPX was downgraded from Buy to Hold, Deutsche Bank said. Valuation call, based on a $12 price target. Pandora ( P) upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. Visibility is improving. $16 price target. Rowan ( RDC) rated new Outperform at Credit Suisse. RDC was initiated with an Outperform rating, Credit Suisse said. $50 price target. Company was also placed on the Focus List. Company trades at a discount to its peers. Vertex Pharmaceuticals ( VRTX) rated new Buy at ThinkEquity. $64 price target. Kalydeco should drive near-term growth.